Full results from the first phase 3 trial of UCB and Biogen's anti-CD40L antibody dapirolizumab pegol (DZP) in systemic lupus erythematosus (SLE) have been revealed, and have not disappointed.
You have to file a claim by next month to receive a payment from AT&T's $177 million privacy settlement. Peter is a writer and editor for the CNET How-To team. He has been covering technology, ...
This data feed is not available at this time. Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback